BRANFORD, Conn., April 27, 2016 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in cloud-based big data platforms and developer of transformative patient treatments, today announced that Dr. Krishnan Nandabalan, Chief Scientific Officer and President, will present at the Third International Conference on the Progress of Regenerative Medicine & its Cultural Impact. The presentation will take place on April 29, 2016 at 4:05 pm CET at Aula Nuova del Sinodo in Vatican City. Dr. Nandabalan’s presentation will be part of a panel entitled A New Paradigm in Drug Discovery and Health Care Delivery Using Technology and Big data. Fellow panelists include Professor Lynda Chin, Associate Vice Chancellor & Chief Innovation Officer at the University of Texas System and Robert High, VP and Chief Technology Officer at IBM Watson.
The conference will feature the world's leading cellular researchers, physicians, ethicists, philanthropists, business leaders, patients and political figures discussing the importance of scientific advancements, technology and data in the evolution of regenerative medicine. BioXcel’s presentation will provide a unique perspective on the challenges of real world data complexity and the adoption and implementation of big data technologies. These approaches enable researchers to decipher important patterns and trends that result in value creation through increased pharma R&D productivity and advance the industry toward its ultimate goal of bringing transformative treatments to patients with high unmet needs.
"There is a tremendous need to identify and apply novel big data approaches for the discovery of new drug candidates in a more effective, cost-efficient manner. The industry can’t continue to spend billions of dollars and patients can’t wait 15-20 years for new drugs to come forward,” said Krishnan Nandabalan, Ph.D., BioXcel’s Chief Scientific Officer and President. “We must rise to the challenge of satisfying this unmet need in both large and niche indications by unleashing the power of our collaborative efforts in a changing landscape where life sciences research, big data, diagnostic, and digital technologies must all converge in the interest of achieving our common goal.”
Eric K. Rowinsky, M.D., Clinical Oncologist for BioXcel added, “We are witnessing firsthand the impact of technology and big data on therapeutic development. This impact is becoming increasingly clear, as BioXcel’s clinical pipeline holds the promise of discovering innovative treatments, such as immunotherapies, that harness the power of the immune system to fight cancer.”
The goal of the event, which was established by the Vatican's Pontifical Council For Culture, The Stem For Life Foundation and the STOQ Foundation, is to engage in discussions about the potential for adult stem cells, and other ethical cellular therapies, to treat cancer, diabetes and other debilitating medical conditions and diseases. This year’s conference will focus on pediatric cancers, rare genetic diseases and diseases that occur with aging.
Attendees who wish to meet with Dr. Nandabalan during the conference should contact: email@example.com, or call: +1 (203) 606-3000.
BioXcel Corporation is a next generation biotechnology company dedicated to improving the probability of the clinical and commercial success of drugs by applying big data analytics. Using a network based pharmacology approach, our first in class Big Data Innovation Lab has generated a clinical pipeline focused on immuno-oncology and CNS orphan diseases, representing a new paradigm for deciphering therapeutic value. Committed to innovation, product excellence and partner success, BioXcel’s global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA.
Tel: 203 957 2487
About Stem For Life Foundation
The Stem For Life Foundation (SFLF) is the educational and advocacy subsidiary of The Cura Foundation and is devoted to fostering global awareness of the potential for regenerative medicine to treat and cure a range of deadly diseases and debilitating medical conditions, as opposed to merely treating their symptoms. The Foundation stands at the forefront of a fundamental shift away from traditional drug treatment in favor of amplifying the body’s natural repair mechanisms to vanquish disease. For more information on The Stem For Life Foundation, please visit http://www.stemforlife.org. To follow the Vatican event on Twitter, please join the conversation @StemForLife or via the hashtag #UNITETOCURE
Stem For Life
Linda Burns, Allison+Partners